Titan Pharmaceuticals currently operates as a pre-revenue entity with no clear path to commercial viability, as evidenced by the complete cessation of product sales and a cumulative retained earnings deficit of $397.8 million. The firm's reliance on external c...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Benchmark TTNP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Titan Pharmaceuticals, Inc. (TTNP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.08 | $4.1M | -0.59 | -100% | — | -103.63% | — | |
| $46.99 | $1.55B | -4.83 | -43.89% | -287.84% | -37.99% | — | |
| $8.50 | $497.72M | 57.71 | -3.63% | 4.83% | 5.4% | — | |
| $4.48 | $183.35M | 2.99 | — | — | 73.03% | — | |
| $21.64 | $2.1B | -42.43 | 504.79% | -0.11% | -0.33% | — | |
| $21.84 | $708.35M | 12.62 | 23.62% | 5.93% | 15.96% | — |
Titan Pharmaceuticals, Inc. (TTNP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TTNP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Titan Pharmaceuticals, Inc. (TTNP) stock FAQ — growth, dividends, profitability & financials explained
Titan Pharmaceuticals, Inc. (TTNP) reported $0.0M in revenue for fiscal year 2024. This represents a 90% decrease from $0.1M in 1995.
Titan Pharmaceuticals, Inc. (TTNP) saw revenue decline by 100.0% over the past year.
Titan Pharmaceuticals, Inc. (TTNP) reported a net loss of $2.8M for fiscal year 2024.
Titan Pharmaceuticals, Inc. (TTNP) has a return on equity (ROE) of -103.6%. Negative ROE indicates the company is unprofitable.
Titan Pharmaceuticals, Inc. (TTNP) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.
